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Abstract: Available evidence shows that human cortical neurons’ and astrocytes’ calcium-sensing 
receptors (CaSRs) bind Amyloid-beta (Aβ) oligomers triggering the overproduction/oversecretion 
of several Alzheimer’s disease (AD) neurotoxinseffects calcilytics suppress. We asked whether 
AβCaSR signaling might also play a direct pro-neuroinflammatory role in AD. Cortical 
nontumorigenic adult human astrocytes (NAHAs) in vitro were untreated (controls) or treated with 
Aβ25-35±NPS 2143 (a calcilytic) and any proinflammatory agent in their protein lysates and growth 
media assayed via antibody arrays, enzyme-linked immunosorbent assays (ELISAs), and 
immunoblots. Results show Aβ•CaSR signaling upregulated the synthesis and release/shedding of 
proinflammatory interleukin (IL)-6, intercellular adhesion molecule-1 (ICAM-1) (holoprotein and 
soluble [s] fragment), Regulated upon Activation, normal T cell Expressed and presumably Secreted 
(RANTES), and monocyte chemotactic protein (MCP)-2. Adding NPS 2143 (i) totally suppressed IL-
6′s oversecretion while remarkably reducing the other agents’ over-release; and (ii) more effectively 
than Aβ alone increased over controls the four agents’ distinctive intracellular accumulation. 
Conversely, NPS 2143 did not alter Aβ-induced surges in IL-1β, IL-3, IL-8, and IL-16 secretion, 
consequently revealing their Aβ•CaSR signaling-independence. Finally, Aβ25-35±NPS 2143 
treatments left unchanged MCP-1′s and TIMP-2′s basal expression. Thus, NAHAs Aβ•CaSR 
signaling drove four proinflammatory agents’ over-release that NPS 2143 curtailed. Therefore, 
calcilytics would also abate NAHAs’ Aβ•CaSR signaling direct impact on AD’s neuroinflammation. 
Keywords: astrocytes; human; calcium-sensing receptor; IL-6; ICAM-1; RANTES; MCP-2; amyloid-
β; neuroinflammation; neurodegeneration 
 
1. Introduction 
Alzheimer’s disease (AD) is the world’s most prevalent form of dementia [1]. Global population 
aging has increased its incidence, making AD a serious familial, healthcare, and societal burden. The 
main AD’s neuropathology hallmarks are amyloid-β (Aβ) senile plaques, hyperphosphorylated Tau 
(hp-Tau) protein neurofibrillary tangles (NFTs), and a chronic diffuse neuroinflammation due to 
activated innate immune pathways in glial cells [2,3]. The inexorably spreading neuropathology 
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causes a worsening neural circuitry breakdown due to the slowly escalating death of neurons and 
oligodendrocytes, which eventually causes the patients’ memory loss, cognitive decline, and ultimate 
demise [4,5]. Previously, the mainstream research focused on the pathogenetic roles played by Aβ 
peptides (Aβs) and hp-Tau proteins, the two main AD drivers [4,5]. More recently, AD’s 
neuroinflammation mechanisms have been attracting increasing attention [2,3]. The brain’s growing 
load of soluble Aβ oligomers drives the activation of astrocytes and microglia. Based on objective 
facts, some authors posit that the induced reactive astrogliosis plays a prominent role in AD’s 
neuroinflammation [6]. In fact, astrocytes are the most abundant brain cell type (from 1.7 to 2.2 fold 
and more the neurons’ number), and the timescale of astrocytes’ proinflammatory signaling lasts 
longer than that of the less abundant microglia [7,8]. However, Aβ-activated astrocytes and microglia 
reciprocally interact with each other by releasing a complex set of agents that sustain and spread the 
neuroinflammation [9]. Here, it is worth pointing out that human cerebral cortex astrocytes do differ 
under significant aspects from their rodent counterparts, e.g., cell subtypes, size, primary processes 
numbers, gap junctions-connected networks, tripartite synapses assembling and disassembling, 
modulation of neurons’ metabolism and functions, physiological blood-brain barrier (BBB) roles, and 
transcriptome profiles [10–14]. Moreover, human astrocytes more intensely perform intricate 
metabolic tasks, e.g. Ca2+ waves propagation, secretion and/or uptake of neurotransmitters, 
gliotransmitters, neuromodulators, hormones, metabolic, trophic, and plastic factors, than rodents’ 
astrocytes do (see for references, [10,15]). Due to a variety of reasons, astrocytes isolated from rodent 
models have hitherto been the preferred experimental models for AD studies. However, it cannot be 
disregarded that the evolutionary changes the human brain has undergone prevent AD-model 
animals from fully mirroring human AD. These hard facts underscore the persistently failed 
translation of promising anti-AD drugs from AD-model animals to human AD patients [6,16,17]. 
Human primary adult astrocytes are isolated directly from brain cortex and retain the morphological 
and functional characteristics of their tissue of origin, so they are reputed the cell culture model that 
more closely represents the human in vivo situation being useful to investigate basic biological 
processes, or manipulate cellular functions and behaviors. It can be argued that the experimental 
exploitation of preclinical “in Petri dishes” AD models involving cortical normal (untransformed) 
adult human astrocytes (NAHAs) and/or neurons and/or microglia is likely to yield results closer to 
the human brain’s physiological or pathological conditions [17].  
The calcium-sensing receptor (CaSR), a member of Family C G-protein-coupled receptors (for 
more details and relevant references see [18,19]), quickly senses changes in extracellular Ca2+ levels 
[Ca2+]e, yet also binds other cations such as polyamines, amino glycoside antibiotics, and Aβs [15,20–
22]. CaSR’s intracellular domains interact with various G-proteins to enact a complex of signaling 
activities, consisting of (i) protein kinases (AKT, PKCs, and MAPKs); (ii) phospholipases (A2, C, and 
D); (iii) transcription factors (TFs); (iv) second messenger production (e.g., cyclic AMP); and (v) Ca2+ 
influx via TRPC6-encoded receptor-operated channels [23,24]. All central nervous system (CNS) cell 
types express CaSRs, though expression levels differ by region, with distinctly high expression in the 
hippocampus [25]. As revealed by RT-PCR and western blot analysis, primary human embryo 
astrocytes express both CaSR mRNA and protein. Meningiomas and astrocytomas too express similar 
levels of CaSR as appraised by northern, RT-PCR, and western blot analyses [26]. Moreover, 
mitotically quiescent nontumorigenic (“normal”) adult human astrocytes (NAHAs) express 
functional CaSRs more intensely than proliferating astrocytes independent of [Ca2+]e changes [27]. 
Apart from controlling general Ca2+ homeostasis (calciostat function) by modulating parathyroid 
hormone (PTH) release, renal Ca2+ reabsorption, and skeletal Ca2+ storage [24,28], CaSRs play extra 
relevant roles in the CNS, physiologically modulating K+ fluxes [29], L-amino acid sensing [30], neural 
cells growth, differentiation, prenatal migration, and postnatal synaptic neurotransmission [25,31–
34]. Changes in expression or altered function of CaSRs also affects CNS diseases, such as AD and 
ischemia/hypoxia/stroke, by regulating outward K+ channel fluxes, nitric oxide (NO) and vascular 
endothelial growth factor A (VEGF-A) overproduction, amyloidogenesis, glial activation, and 
neuronal death [18,20,21,35–38].  
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The use of cortical NAHAs and postnatal HCN-1A neurons as in vitro preclinical models has 
brought to light a novel pathological interaction by which exogenous Aβs bind and activate CaSRs 
[20,21,35] being the Aβ•CaSR complexes subsequently endocytosed in NAHAs [15,35]. Apart from 
the transient overexpression of the CaSR in NAHAs and the progressive overexpression in the 
hippocampal astrocytes and neurons of 3 × Tg AD-model mice [20,39], this interaction drives the 
surplus production, accumulation, and secretion of Aβ42 and hyperphosphorylated Tau oligomers 
from both NAHAs and neurons, coupled with increased cell death among the latter. The CaSR 
agonist NPS R-568 increases Aβ42 oligomers release from NAHAs, mirroring the effect of Aβ25-
35•CaSR signaling [20,21]. At the same time, Aβ•CaSR signaling in astrocytes brings about the 
surplus synthesis/release of NO and VEGF-A [27,35]. Such results implied that diverse 
phenylalkylamines, functioning as CaSR negative allosteric modulators (NAMs or calcilytics; e.g., 
NPS 89636 and NPS 2143) able to move the CaSR response curve to alterations of [Ca2+]e [22,24] may 
be prospective AD medicaments. Calcilytic NPS 2143 stifled all previously mentioned neurotoxic 
effects driven by exogenous Aβ25–35•CaSR signaling and fully preserved neuronal viability [20,21,35]. 
Several reports have linked the CaSR to tissue inflammation and vice versa. In general, CaSR’s 
expression and calciostat function is upregulated by proinflammatory cytokines like interleukin (IL)-
1β and IL-6 produced as part of the innate immune response to tissue damage and inflammation. On 
its own part, the CaSR advances the inflammatory response through multiprotein inflammasomes 
that trigger caspase-1 to produce IL-1β [40]. Lines of evidence indicate the CaSR’s involvement in the 
cytokine-mediated inflammation ensuing deep burn wounds [40], at the level of the airways of 
human allergic asthma patients and of allergen-sensitized mice [41], in adipose tissue [42], colon-
rectum [43], prostate [44], lipopolysaccharide (LPS)-treated lungs [45], and kidneys after ischemia 
and reperfusion in streptozotocin-induced diabetic rats [46]. In fact, CaSR NAM NPS 2143 
administration did elicit an effective anti-inflammatory action in asthma [41] and in LPS-evoked 
pneumonia [45].  
As other laboratories reported, Aβ-exposed animal and human astrocytes release various 
proinflammatory cytokines [3,9,47–50] and chemokines [51–53]. Therefore, in this work we 
investigated whether Aβ•CaSR signaling might also partake in the astrocytes’ excess production and 
secretion of neuroinflammatory agents besides the above-mentioned neurotoxins. The present results 
prove for the first time that NAHAs’ Aβ•CaSR signaling also drives the over-release of 
neuroinflammatory IL-6, soluble intercellular adhesion molecule-1 (s-ICAM-1), Regulated upon 
Activation, Normal T Cell Expressed and Presumably Secreted (RANTES), and Monocyte 
chemotactic protein (MCP)-2. Our findings also show that administering a CaSR NAM [22,24] nearly 
totally or considerably hinders the oversecretion of such neuroinflammatory agents, demonstrating 
further anti-AD beneficial effects of calcilytics to be added to the several ones previously reported 
[15,20,21,35,36,54]. 
2. Materials and Methods 
2.1. Bioethics 
NAHAs were isolated from anonymized surgical fragments of normal adult human temporal 
cortex (brain trauma leftovers) provided by several Neurosurgery Units after obtaining written 
informed consent from all the patients and/or their next-of-kin. Experimental use of isolated NAHAs 
was approved by the Ethical Committee of Verona’s University-Hospital Integrated Company, Prog. 
No. CE118CESC. The ethical approval was obtained on the 1st April 2014 with Protocol number 
15877. All human cells experiments were performed in accordance with the relevant guidelines and 
regulations of Verona’s University-Hospital Integrated Company.  
2.2. Isolation and Culture of Phenotypically Locked-in Nontumorigenic Adult Human Astrocytes (NAHAs)  
Untransformed NAHAs were isolated as previously detailed [21] from temporal lobe cerebral 
cortex leftovers of five male patients (range: 18–38 years) with perforating head injuries due to 
motorcycle accidents who underwent hasty neurosurgery. Briefly, the leftovers were dipped into 
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MCDB 153 medium (Sigma-Aldrich, Milan, Italy), put into a Dewar flask at 4 °C, and carried to the 
laboratory. There they were soon cut into tiny pieces. The cells were released via a mild treatment 
with 0.25% (w/v) trypsin (Gibco, Thermo Fisher Scientific, Monza, MB, Italy) in Hank’s Basal Salt 
Solution (BSS; Gibco, Thermo Fisher Scientific) at 18 °C and the residual pieces were triturated with 
a series of Pasteur pipettes with decreasing (from 5 to 1 mm) bore diameters. The isolated cells were 
planted in 25 cm2 culture flasks (BD Biosciences, Le Pont de Claix, France) containing 2 mL of a 
medium consisting of 89% (v/v) of a 1:1 mixture of Ham’s F-12 and MCDB 153 media (Sigma-
Aldrich,), 10% (v/v) heat-inactivated (at 56 °C for 30 min) fetal bovine serum (FBS; Gibco, Thermo 
Fisher Scientific), and 1% (v/v) of a penicillin–streptomycin solution (Gibco, Thermo Fisher). Basic 
fibroblast growth factor (bFGF or FGF-2; 20 ng mL−1; PeproTech EC Ltd., London, UK), insulin-like 
growth factor-I (IGF-I; 20 ng mL−1; PeproTech), platelet-derived growth factor (PDGF; 20 ng mL−1; 
PeproTech), and epidermal growth factor (EGF; 10 nM; Sigma-Aldrich) were added to the medium 
to enhance the initial proliferation and selection of the astrocytes in the mixed cell population. This 
complete medium was replaced every 2–3 days. When the primary mixed cultures became 70% 
confluent (after 1–4 weeks), the cells were detached from the flask surfaces with 0.25% (w/v) trypsin 
and 0.02% (w/v) EDTA (Gibco, Thermo Fisher) in Hank’s BSS, split 1:4 and planted in new flasks. 
After the third subculture, a pure (100%) population of astrocytes was obtained that no longer needed 
growth factors. Immunocytochemistry and western immunoblot analysis of the cells of these pure 
cultures revealed the expression of only astrocyte-specific markers, such as glial fibrillary acid protein 
(GFAP) and glutamine synthase (GS) (Figure 1). No cells expressed neurons’ (enolase), microglia’s 
(CD-68), oligodendrocytes’ (galactocerebroside), or endothelial cells’ (factor VIII) markers. The 
astrocytes kept proliferating slowly (doubling time, 2–3 weeks) and expressing their characteristic 
markers in 90% (v/v) Ham’s F12/MCDB 153 medium (Gibco, Thermo Fisher) and 10% (v/v) heat-
inactivated fetal bovine serum (Gibco, Thermo Fisher) with no growth factors added. They stopped 
growing but kept expressing their distinctive markers upon reaching confluence or after they were 
incubated in high-Ca2+ (1.8 mM) Dulbecco's Modified Eagle Medium (DMEM, Gibco, Thermo Fisher). 
Thus, they were phenotypically “locked-in”. The proliferatively quiescent cells in confluent astrocyte 
cultures started cycling again when subcultured. The astrocytes kept expressing the CaSR both when 
they proliferated and 1.6-fold more intensely (P < 0.002) when they became mitotically quiescent after 
the exposure to the 1.8 mM Ca2+-containing DMEM. On the other hand, astrocytes’ CaSR expression 
levels were independent of the actual levels of extracellular Ca2+ [27]. Moreover, astrocytes’ CaSRs 
specifically bound exogenous Aβs, and the Aβ•CaSR complexes thus formed were quickly 
internalized [15,35,55]. At least 15–18 subcultures could be obtained over 2.5 years from a tiny piece 
(3–4 mm3) of normal cortex. Only astrocytes from the fourth to the eighth subculture were used for 
the experimental work.  
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Figure 1. Pictures of pure (100%) in vitro cultures of cortical nontumorigenic adult human astrocytes 
(NAHAs) that express their cell type-specific markers glial fibrillary acid protein (GFAP)  (top 
panels) and glutamine synthase (GS) (bottom panels) as detected in immunoblots (left panels) and via 
immunocytochemistry (right panels). NAHAs cultures were set up as detailed in the Materials and 
Methods). After two weeks of staying in vitro, they were sampled and processed for western 
immunoblotting and immunocytochemistry as described in the Materials and Methods. Original 
magnification of the microscope pictures: GFAP, X 100; GS, X 200. 
2.3. Aβ Peptides 
Aβ25–35 (Bachem AG, Bubendorf, Switzerland), a known Aβ1–42 proxy [56], was dissolved at 1.5 
mM in PBS. Fibrillogenesis by Aβ25–35 was checked via thioflavin-T tests before experimental use. The 
reversemer peptide Aβ25–35 (Bachem) was dissolved in the same way as Aβ25–35, yet it did not form 
fibrils and when given to the NAHAs cultures was ineffective (not shown).  
2.4. Experimental Protocol 
Because astrocytes do not normally proliferate in the adult human brain, as in earlier works 
[15,20,21,35,36,52], we used confluent, proliferatively quiescent, NAHAs pure cultures in 1.8 mM Ca2+ 
DMEM (Gibco, Thermo Fisher). At experimental “0 h”, culture flasks (106 NAHAs each) served partly 
as untreated controls receiving a change of fresh medium and partly received fresh medium with 20 
µM of fibrillar (f)Aβ25−35. Exposure of NAHAs to fAβ25−35 lasted for the entire duration of experiments. 
This dose of fAβ25−35 had been found to be ideal in earlier studies [19,20]. The CaSR allosteric 
antagonist (calcilytic) NPS 2143 HCl (2-chloro-6-[(2 R)–3-1,1-dimethyl-2-(2-naphtyl)-ethylamino-2-
hydroxy-propoxy]-benzonitrile HCl; Tocris Bioscience, Bristol, UK) was dissolved in DMSO and next 
diluted in the growth medium at a final concentration of 100 nM. At experimental “0 h”, “24 h”, “48 
h”, and “72 h”, part of the fAβ25−35 astrocyte cultures was exposed for 30 min to NPS 2143 dissolved 
in fresh medium. Next, the NPS 2143-containing medium was removed and fresh (at 0.5 h) medium 
or the previously astrocyte-conditioned (at 24.5 h, 48.5 h, and 72.5 h) media were added again to the 
cultures. Cultured NAHAs and growth media were sampled at 24 h, 48 h, 72 h, and 96 h after the 
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onset of each treatment. Phosphoramidon (10 µM; Sigma), an inhibitor of thermolysin and other 
proteases, was added to the media at “0 h” experimental time.  
2.5. Immunocytochemistry  
Immunostaining of astrocytes, which had been seeded into 24-well plates for primary tissue 
cultures (Becton-Dickinson, Franklin Lakes, NY, USA), was carried out at 4 °C. Astrocytes (2.0 × 
104/chamber) were washed twice with PBS (phosphate-buffered saline) containing BSA (1.0% w/v) 
and NaN3 (0.1% w/v), and incubated for 60 min at room temperature with mouse monoclonal 
antibodies (at 1.0 µg mL–1) against GFAP and GS (both from Santa Cruz Biotechnology Inc., 
Heidelberg, Germany). The cells were washed three times with PBS-BSA solution, next incubated for 
60 min at room temperature with specific secondary antibodies conjugated to horseradish peroxidase 
(all from Santa Cruz Biotechnology). Specific immunostainings were developed with 3, 3′-
diaminobenzidine (Sigma-Aldrich). After a final wash with PBS-BSA solution, specimens were 
examined under an inverted Zeiss IM35 microscope (Carl Zeiss Vision Italia, Milan, Italy) and 
photographed with an Olympus 3300TM (Olympus Life Sciences, Milan, Italy) digital camera. 
Appropriate parallel controls were run with no primary or secondary antibody.  
2.6. Antibody Array 
We found and quantified the proinflammatory cytokines and chemokines detectable in NAHAs-
conditioned media (Table 1) by using the Cytokine Kit RayBioTM Array 3 (RayBiotech, Inc., Peachtree 
Corners, GA, USA), according to the manufacturer’s protocols. Briefly, NAHAs were treated for 48 h 
and 96 h with fAβ25–35 20 µM ± NPS 2143 100 nM. NPS 2143 is a well-established highly selective and 
specific NAM of the CaSR [22,24]. A total of 2 mL of NAHAs-conditioned media sampled 48 h or 96 
h after the onset of the treatments was incubated with the antibody array membranes previously 
treated for 30 min with OdisseyTM blocking buffer (LI-COR Biosciences, Lincoln, NE, USA). Next, 
after a 2 h incubation at room temperature, the array membranes were thoroughly washed and 
incubated for 2 h with 1.0 mL of primary biotin-conjugated antibody, diluted 1:250 in OdisseyTM 
blocking buffer. Finally, the membranes were incubated at room temperature for 1 h with 2 mL of 
DyLight800-conjugated streptavidin (KPL; SeraCare Life Sciences, Milford, MA, USA) diluted 1:7500 
in OdisseyTM blocking buffer. The positive signals of the detected cytokines and chemokines were 
acquired with an OdisseyTM (LI-COR Biosciences) scanner and later quantified using the Image 
StudioTM (version 5.2; LI-COR Biosciences) software. The intensities of the positive signals from each 
array were normalized via comparisons to corresponding positive controls. 
Table 1. Proinflammatory agents analyzed via antibody array in conditioned media of untreated 
NAHAs. 
Cytokines 
Name Gene UniProtKB ID Expression 
Interleukin-1α IL1A P01583 nd 
Interleukin-1β IL1B P01584 + 
Interleukin-2 IL2 P60568 nd 
Interleukin-3 IL3 P08700 + 
Interleukin-4 IL4 P05112 nd 
Interleukin-6 IL6 P05231 + 
Interleukin-7 IL7 P13232 nd 
Interleukin-10 IL10 P22301 nd 
Interleukin-11 IL11 P20809 nd 
Interleukin-12 subunit-α IL12A P29459 nd 
Interleukin-12 subunit-β IL12B P29460 nd 
Interleukin-13 IL13 P35225 nd 
Interleukin-15 IL15 P40933 nd 
Interleukin-16 IL16 Q14005 + 
Interleukin-17A IL17 Q16552 nd 
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Interferon-γ IFNG P01579 nd 
Granulocyte colony-
stimulating factor  
CSF3 P09919 nd 
Granulocyte-macrophage 
colony-stimulating factor 
CSF2 P04141 nd 
Lymphotoxin-α TNFB P01374 nd 
Macrophage colony-
stimulating factor-1 
CSF1 P09603 nd 
Transforming growth factor-
β1 
TGFB1 P01137 nd 
Tumor necrosis factor-α TNFA P01375 nd 
Cytokine Soluble Receptors 
Interleukin-6 receptor 
subunit-α 
IL6R P08887 nd 
TNF receptor superfamily 
member-1α 
TNFRSF1A P19438 nd 
TNF receptor Superfamily 
Member-1β  
TNFRSF1B P20333 nd 
Chemokines 
C-C motif chemokine-1 CCL1 P22362 nd 
C-C motif chemokine-5/ 
RANTES 
CCL5 P13501 + 
C-X-C motif chemokine-9 CXCL9 Q07325 nd 
C-X-C motif chemokine-10 CXCL10 P02778 nd 
Eotaxin-1 CCL11 P51671 nd 
Eotaxin-2 CCL24 O00175 nd 
Interleukin-8 CXCL8 P10145 + 
Monocyte chemoattractant 
protein-1 
CCL2/MCP1 P13500 + 
Monocyte chemoattractant 
protein-2 
CCL8/MCP2 P80075 + 
Macrophage inflammatory 
protein-1α 
CCL3 P10147 nd 
Macrophage inflammatory 
protein-1β 
CCL4 P13236 nd 
Macrophage inflammatory 
protein-5 
CCL15 Q16663 nd 
Other agents 
Soluble intercellular 
adhesion molecule-1 (s-
ICAM-1] 
ICAM1 P05362 + 
Metalloproteinase inhibitor-2 TIMP2 P16035 + 
Platelet-derived growth 
factor subunit-B 
PDGFB P01127 + 
nd, not detected; +, detected. 
2.7. Enzyme-Linked Immunosorbent Assays (ELISAs) of IL-6, MCP-2, RANTES, and Soluble ICAM-1 
Released into NAHAs-Conditioned Growth Media  
To begin, 1x106 NAHAs were seeded in 25 cm2 flasks and cultured with 4 mL of medium, (two 
flasks for each experimental time point). We sampled NAHAs-conditioned growth media taken at 0 
h, 24 h, 48 h, 72 h, and 96 h of exposure to fAβ25−35 20 µM ± NPS2143 and directly stored them at −80 
°C to be later assayed for their IL-6 or MCP-2 or RANTES or soluble (s)-ICAM-1 contents. The same 
cell-conditioned medium samples were tested for assessing IL-6, RANTES, MCP-2 and s-ICAM-1 by 
means of different ELISA kit. Five independent experiments were repeated using NAHAs from as 
many individuals. To do this we used the following commercial kits: Human IL-6 PicoKineTM ELISA 
(Boster Biological Technology Co., Ltd., Pleasanton, CA USA); RayBioTM Human MCP-2 ELISA 
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(RayBiotech); RayBioTM Human RANTES ELISA (RayBiotech); and ICAM-1 (CD54) Human Simple 
Step ELISA (Abcam, Cambridge, UK). We carried out the tests according to the instructions of the 
respective manufacturers. The sensitivity of the assays was < 0.3 pg mL−1 for IL-6, 1.5 pg mL−1 for 
MCP-2, 3 pg mL−1 for RANTES, and 1.6 pg mL−1 for s-ICAM-1. 
2.8. Western Immunoblotting 
First, 1 × 106 NAHAs were seeded in 25 cm2 flasks and cultured with 4 mL of medium, (two 
flasks for each experimental time point). At selected timepoints, we scraped untreated and treated 
NAHAs into cold PBS, sedimented them at 200g for 10 min, and homogenized the pellets in T-PERTM 
tissue protein extraction reagent (Pierce, Rockford, IL) that included a complete EDTA-free protease 
inhibitor cocktail (Roche, Milan, Italy). We determined the protein contents of the samples by using 
the Bio-Rad Protein Assay (Bio-Rad). Briefly, equal amounts (20–30 µg) of protein from the lysates 
were heat-denatured for 10 min at 70 °C in a proper volume of 1× NuPAGE LDS sample buffer 
supplemented with 1× NuPAGE reducing agent (Invitrogen). Next, the lysates were loaded on a 
NuPAGE Novex 4–12% Bis-Tris polyacrylamide gel (Invitrogen, Life Technologies, Monza, MB, 
Italy). After electrophoresis in NuPAGE MES SDS running buffer using the Xcell SureLockTM Mini-
Cell (Invitrogen) (50 min run-time at 200 V constant), proteins were blotted onto nitrocellulose 
membranes using the iBlotTM Dry Blotting System (Invitrogen). Membranes were probed with rabbit 
antihuman IL-6, or rabbit antihuman ICAM-1, or rabbit antihuman RANTES IgG polyclonal 
antibodies (all at a final dilution of 0.5 µg mL−1; Boster Biological Technology), or mouse antihuman 
MCP-2 antibody (at a final dilution 1:500; GeneTex Inc., Irvine, CA, USA), or mouse antihuman GFAP 
antibody and mouse antihuman GS antibody, or goat anti-lamin B1 antibody (at a final dilution of 
1.0 µg mL−1; all from Santa Cruz Biotechnology Inc.). Subsequent processing steps were as previously 
detailed [20]. We used lamin B1 as the loading control. We carried out the densitometric analysis of 
the immunoblots’ specific protein using Image StudioTM (version 5.2, LI-COR) software. 
2.9. Statistical Analysis 
Statistical analysis of the data was performed using SigmaStat® 3.5 Advisory Statistics for 
Scientists (Systat Software, Richmond, CA) and Analyse-it (Analyse-it Software Ltd., UK). 
Densitometric data were normalized to lamin B1 (loading control) and next analyzed by one-way 
ANOVA. When ANOVA’s upshots were significant (P < 0.05) we used post hoc Tukey’s test for all 
pairwise comparisons and multiple comparisons vs. untreated control values. Null hypotheses were 
rejected when P < 0.05. 
3. Results 
3.1. Antibody Array-Detected Changes in Neuroinflammatory Agents Released from Untreated and fAβ25-35 ± 
NPS 2143-Treated NAHAs  
The antibody array we used allowed us to assay 24 cytokines, 3 cytokine agonists, 12 
chemokines, and 3 other agents, all related to inflammatory processes (see Materials and Methods 
and Table 1 for more details). Analysis of media conditioned by untreated (control) NAHAs sampled 
at both 48 h and 96 h after the onset of experiments detected the secretion of 11 compounds, that is 
four cytokines (i.e., IL-1β, IL-3, IL-6, and IL-16) [47,57,58], four chemokines (i.e., IL-8, MCP-1, MCP-
2, and RANTES) [53,59–62], and three other compounds [i.e., metalloproteinase inhibitor-2 (TIMP-2), 
s-ICAM-1, and platelet-derived growth factor subunit-B (PDGF-B)] [63–65] (Table 1, Figure2, and 
Figure S1, Figure S2 in Supplementary Materials). 
The quantitative analysis of the antibody array results revealed that in the untreated NAHA-
conditioned media, IL-6, MCP-1, IL-8, and TIMP-2 had the highest basal levels, whereas IL-1β, IL-3, 
IL-16, and MCP-2 had the lowest ones. Finally, RANTES and s-ICAM-1 had intermediate values 
(Figure 2 and v. Figure S1).  
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Treating NAHAs with fAβ25-35 alone significantly (P < 0.05 vs. controls) increased at 48 h and 96 
h the release of cytokines IL-1β, IL-3, and IL-6, of chemokines IL-8, RANTES, and MCP-2, and also of 
s-ICAM-1 into the conditioned media (Figure 2 and v. Figure S1). Moreover, the exposure to fAβ25–35 
elicited only at 48-h a significant surge (P < 0.05 vs. controls) of cytokine IL-16 (v. Figure S1).  
 
Figure 2. Time-dependent differential expression of (A) Interleukin (IL)-6, (B) Soluble intercellular 
adhesion molecule-1 (s-ICAM-1), (C) Regulated upon Activation, normal T cell Expressed and 
presumably Secreted (RANTES), and (D) Monocyte chemoattractant protein (MCP)-2, the basal 
secretion of which increased after treating NAHAs with fAβ25–35, yet significantly decreased after 
fAβ25–35 + NPS 2143 treatment. Each neuroinflammatory agent was detected in the NAHA-conditioned 
media via membrane-based antibody arrays as described in the Materials and Methods. The 
developed antibody arrays were analyzed in an OdisseyTM (LI-COR) scanner and the positive staining 
intensities of IL-6, s-ICAM-1, RANTES, and MCP-2 were quantified using the Image StudioTM (version 
5.2) software. The integral intensities of the positive signals from each array were normalized via 
comparisons to corresponding controls. Bars are means ± SEMs of three independent experiments, 
each carried out in duplicate. One-way ANOVA followed by post hoc Tukey’s test allowed to 
calculate P values. CTR, untreated controls. * P < 0.05 vs. CTR; ** P < 0.05 of fAβ25–35 alone vs. fAβ25–35 
+ NPS 2143 treatment. 
Conversely, both at 48 h and 96-h, fAβ25-35 alone treatment did not change (P > 0.05 vs. controls) 
the basal secreted amounts of MCP-1, and TIMP-2 (v. Figure S1).  
In summary, the antibody array results allowed us to distinguish three secretion patterns of the 
neuroinflammatory agents into the media from fAβ25–35 ±NPS 2143-treated NAHAs:  
(i) a significant increase elicited by fAβ25–35 treatment, which fAβ25–35 + NPS 2143 cotreatment 
brought back to control levels by 96 h as was typical of IL-6, MCP-2, and soluble (s)-ICAM-1 fragment, 
whereas it only partially reduced RANTES secreted levels (Figure 2);  
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(ii) a significant increase brought about by fAβ25–35 exposure that did not change when adding 
NPS 2143 to fAβ25–35, as was proper of IL-1β, IL-3, and IL-8 at both 48 h and 96 h, whereas the surge 
of IL-16 at 48-h was only transient (v. Figure S1); and 
(iii) no change vs. control levels after the addition of either fAβ25–35 by itself or fAβ25–35 + NPS 
2143, as exemplified by MCP-1 and TIMP-2 (v. Figure S1). 
These findings revealed for the first time that the AD-typical chronic neuroinflammation can be 
advanced by the NAHAs’ Aβ•CaSR signaling-elicited secretion of proinflammatory cytokine IL-6, 
chemokines RANTES and MCP-2, and of the s-ICAM-1 fragment.  
3.2. Calcilytic NPS 2143 Effectively Hinders the Secretion of IL-6, MCP-2, RANTES, and s-ICAM-1 from 
NAHAs  
To expand and validate the above antibody array findings, we used more sensitive ELISA tests 
to assay the amounts of IL-6, MCP-2, RANTES, and s-ICAM-1 fragment released into the growth 
media from NAHAs treated for 24 h, 48 h, 72 h, and 96 h with fAβ25–35 ± NPS 2143.  
3.2.1. IL-6 Secretion into NAHA-Conditioned Growth Media  
The results of time-course ELISA assay revealed that Aβ•CaSR signaling directly and linearly 
increased the secreted amounts of IL-6 for up to 72 h, when it peaked at a 2.6-fold (P < 0.05) value 
over untreated controls and remained so high even at 96 h (Figure 3A). However, adding CaSR NAM 
NPS 2143 significantly (P < 0.05) suppressed at all time points the fAβ25–35-elicited IL-6 surplus 
secretion over parallel control values (Figure 3A). Accordingly, the cumulative (as estimated from 
the areas under the corresponding curves) 0 h to 96 h surplus release of IL-6 over control levels 
(+80.4%; P < 0.05) elicited by fAβ25–53 itself decreased to insignificance (+14.9%, P > 0.05 vs. controls; 
−81.5%, P < 0.05 vs. fAβ alone) when NAHAs were cotreated with fAβ25–53+NPS 2143 (Figure 3A; Table 
2), thereby confirming the corresponding array data (cf. Figure 2). Therefore, pathological Aβ•CaSR 
signaling elicited most of the IL-6 oversecretion from NAHAs as calcilytic NPS 2143 effectively 
suppressed it.  
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Figure 3. Changes in released levels of (A) IL-6, (B) s-ICAM-1, (C) RANTES, and (D) MCP-2 in 
NAHAs treated with fAβ25–35±NPS 2143 vs. untreated controls (CTR). Each agent was assessed in the 
NAHA-conditioned media via a specific ELISA kit as detailed in the Materials and Methods. Points 
on the curves are means ± SEMs of 3–5 independent experiments, each carried out in duplicate. One-
way ANOVA followed by post hoc Tukey’s test allowed us to calculate P values. * P < 0.05 vs. time-
corresponding CTR values; # P < 0.05 vs. 0-h CTR value; ** P < 0.05 vs. fAβ25–35 + NPS 2143 values. 
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Table 2. Impact of calcilytic NPS 2143 on fAβ25–35-evoked cumulative 0-h-to-96-h secretion/shedding 
of neuroinflammatory agents from NAHAs. 
 Treatments 
Cumulative 
Secretion§ 
% Changes 
vs. CTR 
% Changes vs. 
fAβ25–35 
IL-6 CTR 502.1 ± 39.6     
  fAβ25-35 905.6 ± 48.4 +80.4*   
  fAβ25–35 +NPS 2143 576.9 ± 41.0 +14.9 −81.5* 
s-ICAM-1  CTR 30.6 ± 2.3     
  fAβ25–35 59.7 ± 2.7 +95.1*   
  fAβ25–35 + NPS 2143 41 ± 2.6 +34.0* −64.3* 
RANTES CTR 42.9 ± 13.3     
  fAβ25–35 226 ± 17.2 +426.8*   
  fAβ25–35 + NPS 2143 149.3 ± 7.4 +248.0* −41.9* 
MCP-2 CTR 185.9 ± 29.3     
  fAβ25–35 6897.9 ± 248 +3611.0*   
  fAβ25–35 + NPS 2143 2717.6 ± 320 +1361.9* −62.3* 
§ Expressed as mean values ± SEM of the areas under the respective 0 h-to-96 h curves. *, P < 0.05. CTR, untreated 
controls. 
3.2.2. s-ICAM-1 Shedding into NAHA-Conditioned Growth Media 
The time-course ELISA assay results showed that the amount of s-ICAM-1 that untreated 
NAHAs shed at 48 h, 72 h, and 96 h into the medium increased by 2.0/2.4-fold (P < 0.05) over 0-h and 
24 h values (Figure 3B). On the other hand, during the first 24-h s-ICAM-1 shedding from fAβ25–35 
alone-treated NAHAs did not significantly (P > 0.05) change vs. untreated control values. 
Subsequently, the fAβ25–35 treatment briskly raised s-ICAM-1 release making it reach by 48 h and 72 
h 2.5-/2.4-fold higher values than parallel controls’ (P < 0.05); thereafter, it only slightly declined (96 
h, 2.2-fold controls values, P < 0.05) (Figure 3B). Adding NPS 2143 to fAβ25–35 treatment significantly 
(P < 0.05 at all time points) curbed the Aβ•CaSR signaling-elicited s-ICAM-1 surplus shedding over 
basal (control) levels (Figure 3B). The cumulative (0 h to 96 h areas under the curves) s-ICAM-1 
amount shed over control levels (+95.1%, P < 0.05) from the fAβ25–35 alone-treated NAHAs was cut 
remarkably down by NPS 2143 addition (vs. controls, +34.0%, P < 0.05; vs. fAβ25–35 alone, −62.3%, P < 
0.05) (Table 2). Therefore, pathological Aβ•CaSR signaling was specifically responsible for the quota 
(62.3%) of the IL-6 surplus shed over control levels that calcilytic NPS 2143 suppressed.  
3.2.3. RANTES Secretion into NAHA-Conditioned Growth Media 
As the time-course ELISA assay results showed, once exposed to fAβ25–35 alone, NAHAs secreted 
the same amounts of RANTES as controls did during the first 24 h. Next, fAβ25–35 alone-exposed 
NAHAs hugely increased RANTES release between 24 h and 72 h to moderately decrease it between 
72 h and 96 h (48 h, +389%; 72 h, +355%; 96 h, +250%; P < 0.05 at each time point vs. untreated controls). 
Adding NPS 2143 partially yet significantly (P < 0.05 at each time point) curtailed the fAβ25–35-elicited 
RANTES surplus secretion over controls’ baseline (Figure 3C). Thus, the cumulative (0 h to 96 h) 
fAβ25-35 alone-elicited RANTES surplus secretion over controls (+426.8%, P < 0.05) was considerably 
reduced (vs. controls, +248%, P < 0.05; vs. fAβ25–35 alone, −41.9%, P < 0.05) in the media from fAβ25–
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3+NPS 2143-treated NAHAs (Table 2). Just as for s-ICAM-1, pathological Aβ•CaSR signaling 
specifically drove a conspicuous part (64.3%) of the RANTES surplus secretion from NAHAs that 
calcilytic NPS 2143 suppressed.  
3.2.4. MCP-2 Secretion into NAHA-Conditioned Growth Media 
The time-course ELISA results showed that untreated (control) NAHAs steadily secreted very 
low basal MCP-2 amounts (1.9 pg mL−1) into the culture media. However, in keeping with 
corresponding protein array results, the treatment with fAβ25–35 alone hugely increased the secreted 
amounts of MCP-2 vs. untreated parallel controls (24 h, +1134%; 48 h, +6400%; 72 h, +8122%; 96 h, 
+5443%; P < 0.0001 at all time points). Conversely, after no change during the first 24 h, the NPS 2143 
+ fAβ25-35 cotreatment significantly cut down MCP-2 releases vs. fAβ25–35 alone-treated values (48 h, 
+2186%; 72 h, +2357%; 96 h, +1043%; P < 0.0001 at all time points) (Figure 3D). Thus, the cumulative 
(0 h to 96 h) fAβ25–35-elicited MCP-2 secretion surplus over controls (+3611.0%, P < 0.0001) significantly 
decreased with the NPS 2143 +fAβ25-35 treatment (vs. controls, +1361.9%, P < 0.05 ; vs. fAβ25–35 alone, 
−62.3.9%, P < 0.05) (Table 2). Therefore, just as for s-ICAM-1 and RANTES, pathological Aβ•CaSR 
signaling specifically drove an important quota (62.3%) of the MCP-2 surplus secretion from NAHAs 
that NPS 2143 suppressed.  
In conclusion, the Aβ•CaSR signaling involvement was shown by the ability of CaSR NAM NPS 
2143 to significantly reduce the amounts of the just mentioned neuroinflammatory agents that 
NAHAs secreted/shed. 
3.3. Changes in Cytokine/Chemokine Levels in NAHAs Protein Lysates Evoked by with fAβ25-35 ± NPS 2143 
Treatments 
3.3.1. IL-6 Expression in NAHA Protein Lysates 
Densitometric analysis of immunoblots specific bands showed that after a 24 h delay the lysates’ 
IL-6 levels rose significantly (+90.1% by 48 h; + 77.3% by 72 h; P < 0.05 vs. 0 h control levels in both 
instances) in fAβ25–35-treated NAHAs. Conversely, the NPS 2143 + fAβ25-35 treatment promptly 
increased the lysates’ IL-6 amounts (24 h, +111%; 48 h, +101%; 72 h, +73.3%; P < 0.05 vs. 0 h levels in 
all instances) (Figure 4A). Thus, by hindering extracellular release, NPS 2143 treatment favored an 
early intracellular accumulation of IL-6 which concurred with a decrease in IL-6 secretion (cf. Figure 
3A). 
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Figure 4. Changes in protein lysates’ levels of (A) IL-6, (B) s-ICAM-1, (C) RANTES, and (D) MCP-2 in 
NAHAs treated with fAβ25–35±NPS 2143 vs. untreated controls (CTR). At the top of each panel are 
typical immunoblots showing the densitometric changes of each agent according to treatments vs. 
untreated controls (CTR). LC, loading control. The graphs underneath show the densitometric 
evaluations of the specific bands at each time point of every treatment. Points on the curves are mean 
values of three independent experiments, each carried out in duplicate with control (0-h) values 
normalized as 1.0. One-way ANOVA followed by post hoc Tukey’s test allowed to calculate P values. 
* P < 0.05 vs. CTR; ** P < 0.05 vs. fAβ25–35 + NPS 2143. 
3.3.2. ICAM-1 Holoprotein Expression in NAHA Protein Lysates 
The exposure to fAβ25–35 alone increased in a linear fashion over basal levels the ICAM-1 
holoprotein contents of NAHAs lysates (24 h, +267%; 48 h, +600%; 72 h, +1061%; P < 0.001 at all time 
points examined) (Figure 4B). In NPS, 2143 + fAβ25-35 co-exposed NAHAs the intracellular ICAM-1 
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holoprotein levels speedily rose between 0 h and 24 h (+600%; P < 0.001) to keep raising more slowly 
thereafter (48 h, +700%; 72 h, +760%; P < 0.001 in both instances). Thus, fAβ25–35 by itself remarkably 
increased the intracellular accumulation of the ICAM-1 holoprotein. The NPS 2143 addition only 
intensified the ICAM-1 holoprotein accumulation during the first 24 h while reducing it by 72 h vs. 
fAβ25–35 alone values. This happened just while the s-ICAM-1 fragment shedding significantly 
decreased or fell to basal levels (cf. Figure 3B). At variance with the three other agents investigated, 
NPS 2143 addition likely promoted the ICAM-1 holoprotein intracellular proteolysis instead of its 
accumulation, while hindering the s-ICAM-1 fragment extracellular shedding. 
3.3.3. RANTES Expression in NAHAs Protein Lysates 
In protein lysates from NAHAs exposed to fAβ25–35 by itself RANTES levels were lower than 
basal (0-h) values (24 h, −43%; 48 h, −57%; P < 0.05 at both time-points), to raise over basal values by 
72 h (+36%; P < 0.05). Adding NPS 2143 to fAβ25–35 initially increased RANTES levels in NAHAs 
lysates over basal (0-h) values (24 h, +93%; 48 h, +43%; P < 0.05 in both instances), but reduced them 
below basal values at 72 h (−29%; P < 0.05) (Figure 4C). Thus, the NPS 2143-antagonized Aβ•CaSR 
signaling favored the intracellular accumulation of RANTES while partially lessening its secretion 
(cf. Figure 3C). 
3.3.4. MCP-2 Expression in NAHA Protein Lysates 
In lysates from fAβ25–35 alone-exposed NAHAs, MCP-2 protein was significantly upregulated at 
24-h (+267%, P < 0.001 vs. basal [0-h] values), to decline thereafter yet remaining higher than basal 
levels (48 h, +100%; 72 h, +67%; P < 0.05 at both time-points). Adding NPS 2143 to fAβ25–35-treatment 
linearly increased the MCP-2 contents (24 h, +156%; 48 h, +311%; 72 h, +556%; P < 0.001 at all time-
points vs. basal [0 h] levels) in NAHA lysates (Figure 4D). Thus, by hindering Aβ•CaSR signaling 
NPS 2143 addition promoted the intracellular accumulation of MCP-2 while significantly hindering 
its secretion (cf. Figure 3D). 
4. Discussion 
The present findings offer the first evidence ever that Aβ•CaSR signaling drives an increased 
synthesis and extracellular secretion/shedding of four proinflammatory agents, i.e., IL-6, ICAM-1/s-
ICAM-1, RANTES, and MCP-2, from proliferatively quiescent cortical NAHAs (Figure 5). These 
results add a further noxious dimension to the previously reported multiple damaging effects that 
the pathological signaling from Aβ•CaSR complexes elicits in cultured NAHAs [18–21,35,36,39,54]. 
Most important, our results also show that a paradigmatic CaSR NAM, i.e. NPS 2143, can significantly 
suppress or abate NAHAs’ secretion/shedding of the same four proinflammatory mediators. 
Abundant data in the literature prove that these same agents concur to evoke significant 
neuroinflammatory effects in vivo (cf. Table 3). Activated astrocytes and microglia, the brain’s innate 
immune system cells, partake in neuroinflammation by producing and releasing copious amounts of 
cytokines, chemokines, and other agents [50–53,66,67]. Chemokine-attracted circulating immune cells 
cross a dysfunctional BBB and release proinflammatory agents intensifying the CNS tissue damage 
(see for reviews [2,3]). As the abundant literature on the topic makes clear (see for reviews [3,68]), the 
main mechanisms of inflammatory signaling develop as an integrated pattern forming a biological 
signaling network. In fact, once cytokines are secreted in response to initial signals, they can bind to 
their own receptors and trigger both cytosolic and nuclear signal amplification pathways (i.e., NF-
κB, JNK [c-Jun N-terminal kinase), p38 MAPK (mitogen activated protein kinase), STAT (signal 
transducers and activators of transcription), and PI3K (phosphatidylinositol-3-kinase) that crosstalk 
with one another resulting in complex intracellular signaling networks. Reciprocal astrocytes-
microglia interactions [9] lead to self-strengthening positive feedback loops perpetuating and 
spreading the neuroinflammation. Reportedly, IL-1β, IL-6, TNF-α, and IFN-γ are the main pro-
inflammatory cytokines involved in AD brains [51,66,67,69]. Several chemokines, e.g., MCP-1 (or 
CCL2), RANTES (or CCL5), CCL23, IL-8 (or CXCL8), and IP-10 (or CXCL10) are involved too as they 
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recruit peripheral immune cells into the CNS [51,67,69]. Neuroinflammation exacerbates the course 
of both acute (e.g., stroke) and chronic (e.g., AD, Parkinson, etc.) diseases by self-propagation and by 
causing neuronal excitotoxicity and loss of synapses [9,50–53,66]. Regarding AD, some reports 
suggest that microglial inflammatory mediators like IFN-γ and TNF-α cause Aβs overproduction 
and deposition by hindering Aβs clearance in mutant APP transgenic mice and in cocultures of 
astrocytes and microglia from the same mutant and wild-type mice [70,71]. At variance with these 
results in rodents, microglial cytokines only transiently accelerated endogenous Aβs release from Aβ-
exposed NAHAs [21]. The use of antibody arrays has allowed us to find the four proinflammatory 
agents that are driven by Aβ•CaSR signaling in NAHAs and are hindered by the CaSR NAM 
presently employed. 
 
Figure 5. Synopsis of the direct pro-neuroinflammatory effects pathological Aβ•CaSR signaling 
evokes in NAHAs. The administration of a CaSR negative allosteric modulators (NAM) nearly totally 
switches off (in the case of IL-6) or remarkably mitigates (in the case of MCP-2, s-ICAM-1, and 
RANTES) the Aβ•CaSR signaling-evoked noxious pro-neuroinflammatory upshots. “” denotes 
upregulation. Abbreviations as in the text. 
4.1. IL-6 
The present findings show that Aβ•CaSR signaling strongly increases both the synthesis and 
release of IL-6 from NAHAs. Conversely, calcilytic NPS 2143 suppresses most of this IL-6 surplus 
release while increasing its amounts in NAHAs lysates. The latter finding might be ascribed to the 
blocking effect of the IL-6 secretory pathway at the Golgi apparatus level [72] that CaSR NAM NPS 
2143 exerts, which affects the secretion of other compounds including endogenous Aβ42 [20] and 
likely also RANTES and MCP-2 (see below). Further studies will clarify whether the slow decline in 
intracellular levels of IL-6 occurring after early peaking is due to decreased synthesis or increased 
lysis or both. It is well established that IL-6 and its downstream JAK/STAT3 signaling pathway exert 
pleiotropic effects closely related to our previous and present findings, that is the upregulation of the 
transcription of several genes including ICAM-1, RANTES, MCP-2, VEGF-A, and CASR [73–75]. On 
this basis, we posit that IL-6 overexpression driven by Aβ•CaSR signaling partakes in the control of 
CASR, ICAM-1/s-ICAM-1, RANTES, and MCP-2 genes upregulation in NAHAs. Moreover, 
overproduced IL-6 accumulates around and inside senile plaques in the cerebral cortex and 
hippocampi of AD patients [76,77]. IL-6 also increases Tau protein hyperphosphorylation in neurons 
of AD brains through the cdk5/p35 and the MAPK-p38 signaling pathways [78]. Conversely, the 
results of studies about IL-6 in AD-model animals have so far been contradictory. In the astrocytes 
residing in the hippocampus and cerebellum of transgenic mice, increased IL-6 levels upregulated 
the expression of GFAP, glutamine synthase, STAT-3, phosphorylated STAT-3, and phosphorylated 
pp42/44 MAPK, but downregulated that of Synuclein 1, GAD65/67, GluA1, and GluN1 [79]. Recent 
reports revealed that the JAK/STAT3 pathway acts as pivotal driver of astrocyte reactivity [80] and 
that inhibiting the Stat3-mediated astrogliosis ameliorates the neuropathology in mouse models of 
AD [81]. Brugg et al. [82] reported that peripheral stimulation with LPS induced transient elevations 
in both IL-6 and IL-1β mRNAs followed by changes in the expression pattern of APP isoforms (i.e., 
decreases in APP695 and increases in APP KPI levels) in the cerebellum but not in the cerebral cortex 
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of mouse brain. This concurrent upregulation of both IL-6 and APP during acute neurological stress 
or chronic neurodegeneration suggested an interlinked expression of these two proteins. However, 
as a cautionary note, we must mention here that NAHAs are insensitive to LPS exposure (our 
unpublished results) and, as the present findings show, IL-6 upregulation is completely or nearly 
completely controlled by Aβ•CaSR signaling in NAHAs. 
4.2. ICAM-1 Holoprotein/s-ICAM-1 
The present results show that the exposure to exogenous Aβs progressively raised ICAM-1 
holoprotein’s levels in NAHAs lysates and, after a 24-h delay, even s-ICAM-1 fragment’s levels in 
NAHA-conditioned media. They also reveal for the first time that by antagonizing Aβ•CaSR  
signaling calcilytic NPS 2143 deeply (i.e., by about 64%; Table 2) cut down s-ICAM-1 fragment’s 
extracellular shedding from NAHAs while prompting an early and persistent increase of ICAM-1 
holoprotein amounts in NAHA lysates. It is well known that cell adhesion molecules, including 
ICAM-1, regulate both physiological interactions between neural cells and the extracellular 
environment and pathological mechanisms underlying neurodegenerative diseases (reviewed in 
[83,84]). Belonging to the immunoglobulin (Ig) supergene family, the heavily N-glycosylated ICAM-
1 (CD54) is an (Ig)-like holoprotein (~100 kDa) expressed by activated GFAP+ astrocytes and microglia 
both in the CNS grey and white matter and in vitro. ICAM-1′s Ig domains bind several leukocytes’ 
ligands including CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1), β2-integrins (p150,95 and Mac-1), and 
more. The binding of ligands to ICAM-1 homodimers’ [85] activates Akt, ERK, and JNK signaling 
pathways regulating (i) the synthesis of cytokines, chemokines, and adhesion molecules; and (ii) 
leukocytes’ traffic across the BBB (see references in [86]). Proteolysis of the membrane-inserted 
ICAM-1 ectodomain by cathepsin G, neutrophil elastase, and ADAM-17/TACE sheds the soluble s-
ICAM-1 fragment (85 kDa) into the extracellular space, circulating blood, and cerebrospinal fluid 
(CSF) [86–88]. Microglial cytokines (e.g., IFN-β1a, IFN-γ, and TNF-α) and Staphylococcus enterotoxin 
B regulate s-ICAM-1 fragment’s shedding from endothelial cells, peripheral monocytes [87,89], and 
human cortical fetal astrocytes [64]. Sloughed off s-ICAM-1 fragment binds the same ligands as 
transmembrane ICAM-1 holoprotein does to activate leukocytes [90]. s-ICAM-1 also prevents 
leukocytes from binding membrane-inserted ICAM-1 holoprotein’s ectodomain [88]. Under 
physiological conditions, the basal expression of both ICAM-1 holoprotein and s-ICAM-1 fragment 
is weak and mostly occurs in endothelial cells. Various cytokines, including IL-6, RANTES, IL-1β, 
TNF-α, and IFN-γ upregulate the expression of both ICAM-1 holoprotein and s-ICAM-1 fragment, 
which in turn actively drive inflammatory responses and hence are inflammation markers [64,89–93]. 
Studies comparing s-ICAM-1′s with soluble E selectin’s expression levels in AD brains indicated that 
s-ICAM-1 fragment surpluses arise from neural cells (likely astrocytes) rather than from endothelial 
cells, since soluble E selectin levels, an exclusive marker of endothelial cells activation, remained 
unchanged [94].  
Based on the just mentioned data in the literature, our findings suggest that by increasing both 
IL-6 and RANTES expression Aβ•CaSR signaling boosted a sizeable chunk of s-ICAM-1 fragment’s 
shedding from NAHAs. The calcilytic-non-suppressible portion of s-ICAM-1′s increased shedding 
might have been brought about by the concurrently Aβ-elicited IL-1β upregulation [86,87,95], which 
as our results show, is independent of Aβ•CaSR signaling. Further studies will assess this hypothesis. 
Conversely, the observed ICAM-1 holoprotein increases in NAHA lysates are likely to be due to 
different operative mechanisms. On its own part, Aβ•CaSR signaling might increase ICAM-1 
holoprotein synthesis and its insertion and cleavage at the NAHAs plasma membrane. On the other 
hand, the calcilytic might hinder plasma the ICAM-1 holoprotein membrane insertion and cleavage. 
Although the details about the molecular mechanisms involved are not understood, our results 
clearly show that the addition of NPS 2143 to Aβ-exposed NAHAs did significantly cut down the 
potential proinflammatory actions of both ICAM-1 holoprotein and s-ICAM-1 fragment. The 
following evidences will allow us to better appreciate the prospective relevance of these findings. 
Remarkable increases in extravascular s-ICAM-1 around GFAP+ astrocytes connote the orbitofrontal 
cortex of normally aging people and might mark an increasing with age risk of neuroinflammatory 
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diseases [88]. In postmortem AD brains, s-ICAM-1 aggregates localize to peri-plaque astrocytes, early 
and late stage amyloid senile plaques, and cerebral vessels [96–98]. Serum levels of s-ICAM-1 are low 
in healthy subjects [89]. In AD cases, s-ICAM-1 levels raise in both blood and CSF, mirror the 
upsurges in transmembrane ICAM-1 holoprotein, positively correlate with illness severity [90,91,95], 
and partake in BBB’s dysfunction thus advancing immune cells infiltration into the CNS and hence 
neuroinflammation. 
4.3. RANTES 
Astrocytes are the main source of RANTES, a powerful chemokine that attracts and activates 
eosinophil and basophil leukocytes. The present results show that, after a 24 h delay, Aβ-exposed 
NAHAs released significantly higher RANTES amounts while reducing its levels in the cells’ lysates. 
The 24 h time lag preceding the onset of RANTES over-release suggests that its driving mechanism(s) 
is(are) complex requiring the synthesis of some intermediate agent(s). Microglial cytokines like TNF-
α and IFN-γ upregulate RANTES expression in human and simian astrocytes [66]. However, these 
cytokines were undetectable in our experimental system. Of greater interest is the notion that IL-1β 
mediates RANTES expression in human fetal astrocytes via the activation of IFN regulatory factor 3 
(IRF3]. In its turn, IFR3 induces a group of IFN-stimulated antiviral response genes (ISG) including, 
besides RANTES, IFN-β, IRF7, and CXCL10/IFN-γ-inducible protein-10 [62,99]. Whether this IL-1β-
triggered mechanism also works in the Aβ-treated NAHAs that, as our results show, overexpress IL-
1β (Figure S1), seems likely yet remains to be proven. Lin et al. [100] also reported that the activation 
of PI3K and MAPK signaling pathways upregulated RANTES expression in curcumin-treated 
primary rat astrocytes. Because Aβ•CaSR signaling activates MEK/ERK signaling in NAHAs [101], 
this mechanism could also help up-regulate RANTES. This view is supported by our observation that 
CaSR NAM NPS 2143 significantly curbed a substantial fraction (i.e., 42%; Table 2) of RANTES release 
from NAHAs likely via a block of its secretory pathway through the Golgi apparatus—a mechanism 
also shared by IL-6, MCP-2, and endogenous Aβ42 [21,102,103]. On the other hand, the fall of 
immunodetectable RANTES in lysates from Aβ-exposed NAHAs suggests that over synthesized 
RANTES is secreted into the medium with no delay just as happens for VEGF-A [35]. Moreover, our 
observation that after peaking at 24-h the RANTES overaccumulation progressively vanished in 
Aβ+NPS 2143-treated NAHAs might result from (i) an initial block of RANTES secretory pathway 
through the Golgi apparatus; and (ii) a later decline of RANTES de novo synthesis coupled to a rescue 
of proteasomal activity [21]. Clearly, a detailed definition of the mechanisms involved requires 
further investigations. Our results suggest as likely that RANTES over-release from Aβ-exposed 
NAHAs partakes in the multiple proinflammatory effects evoked by Aβ•CaSR signaling and by an 
Aβ exposure in general, which is in keeping with the views of authors positing that RANTES is a 
relevant player in the inflammatory cascade that advances AD neurodegeneration [62,104,105]. As it 
does in murine astrocytes, RANTES by itself also strongly stimulates the production and release of 
proinflammatory mediators, including s-ICAM-1 [94,106]. It is worth mentioning here the 
interactions of secreted RANTES with its three receptors, i.e., CCR1, CCR3, and CCR5, which drive 
autocrine mechanisms affecting astrocytes secretory functions [106]. Of note, the activation of 
RANTES receptors entails their coupling with inhibitory Gi/o protein, which cuts down adenylyl 
cyclase activity and thus lowers the synthesis of neurotrophic cyclic 3′,5′-adenosine monophosphate 
(cAMP) in mouse astrocytes [93]. Previously, we showed that CaSR NAM NPS 2143 rescued the Aβ-
curtailed cAMP production and release from NAHAs [21]. Whether the signaling pathways of CASR 
and RANTES receptors crosstalk between each other is to be determined in NAHAs. Finally, on a 
discordant note, Grammas et al. [105,107] reported that RANTES upregulation assists neurons’ 
survival in vitro by protecting them against the noxious effects of AD neurotoxins, thrombin, and 
sodium nitroprusside. Therefore, further studies will clarify whether RANTES plays a double-face 
role according to the actual stage of AD neuroinflammation. 
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4.4. MCP-2 
Human MCP-2 is a small chemokine encoded by the CCL8 gene. MCP-2 pertains to a subfamily 
of the C-C or β-chemokines also including MCP-1 and MCP-3 sharing a 60–62% sequence identity 
[61]. The present findings prove for the first time that Aβ-exposed NAHAs quite intensely oversecrete 
MCP-2 with respect to basal values. They also show that adding calcilytic NPS 2143 cuts down a 
significant fraction (62.3%; Table 2) of the Aβ•CaSR signaling-driven MCP-2 oversecretion. MCP-2 
only moderately accumulated in lysates from Aβ-treated NAHAs apparently because its 
oversecretion balanced most of its overproduction. However, the linearly progressive and much 
more pronounced MCP-2 accumulation in lysates from Aβ+NPS 2143-treated NAHAs suggests that 
NPS 2143 blocked MCP-2 secretion through the Golgi pathway, as did with IL-6, RANTES, and 
endogenous Aβ42 [21,102,103], without interfering with its accelerated synthesis. Further work will 
assess this postulation. As a chemokine, MCP-2 is both less potent and less effective than MCP-1, 
MCP-3, and RANTES [61,108]. But, as our findings show, basal MCP-1 expression did not change in 
Aβ-treated NAHAs (Figure S1). Reportedly, MCP-2 activates the chemotaxis of human lymphocytes 
T, NK cells, and monocytes, which take part in inflammatory responses, and of eosinophils, 
basophils, and mast cells, which partake in allergic reactions. Concerning AD, most of the existing 
literature focuses on the proinflammatory role of MCP-1. Conversely, the available data about MCP-
2 role(s) in AD are scanty. Just like MCP-1, CCL7, CCL12, and CCL13, MCP-2 enhances the 
chemotaxis of proinflammatory cells towards inflamed areas of the CNS [109]. As happens with 
MCP-1, CSF MCP-2 levels might increase in AD patients, suggesting its association with 
neurodegeneration [108]. In addition, CSF levels of MCP-2 might be a good risk predictive marker 
for early stage AD and other psychoses [110]. Aβ•CaSR signaling and other hitherto unidentified 
factors may drive MCP-2 oversecretion from NAHAs. Next, MCP-2 would recruit monocytes and/or 
other leukocyte populations into the brain, thereby enhancing neuroinflammation and neuronal 
injury, thus contributing to AD’s progression via mechanisms not detectable by the presently used 
experimental system. Based on our findings, it seems workable that by antagonizing Aβ•CaSR 
signaling, calcilytics could significantly diminish MCP-2 role in AD’s neuroinflammation. Clearly, 
further studies should specifically address and clarify MCP-2′s role(s) in human AD. 
Table 3. IL-6, s-ICAM-1, RANTES, and MCP-2 drive complex neuroinflammatory responses. 
Agent Proinflammatory Roles 
IL-6 
Induces extensive gliosis and microglial phagocytosis of Aβs deposits in vivo [77]  
Increases Tau protein hyperphosphorylation in neurons [78]  
Increases the levels of hippocampal and cerebellar GFAP, glutamine synthase, STAT-3, 
phosphorylated STAT-3, and phosphorylated pp42/44 MAPK [79]  
Decreases the levels of Syn 1, GAD65/67, GluA1, and GluN1 [79]  
Upregulates CASR gene transcription [75]  
Upregulates the transcription of several other genes including ICAM-1, RANTES, MCP-2, VEGF-
A [73,74] 
s-ICAM-
1 
Promotes lymphocytes and leukocyte trafficking through the BBB [87]  
Partakes in BBB dysfunction and CNS infiltration by immune cells [87]  
Localizes to vessels, early and late stage amyloid senile plaques, and peri-plaque astrocytes in 
AD brains [96,97] 
RANTES 
Attracts and activates eosinophil and basophil leukocytes [104]  
Is relevant to the neuroinflammatory cascade that contributes to neurodegeneration in AD 
brains [62,104]  
Stimulates astrocytes’ production and release of proinflammatory mediators [93,106]  
The RANTES/CCR3 signaling lowers the endogenous levels of cAMP [106]  
May contribute to upregulating the s-ICAM-1 levels [93] 
MCP-2 
Enhances chemotaxis of proinflammatory cells (monocytes or other leukocyte populations) to 
inflamed CNS areas [109] 
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4.5. Other Proinflammatory Agents Not Affected by Antagonizing Aβ•CaSR Signaling 
See Supplementary Data. 
5. Conclusions 
The present results are the first evidence that Aβ•CaSR signaling is directly involved in AD’s 
neuroinflammation via the over-release/shedding of four proinflammatory agents from NAHAs. 
This is a further addition to the previously reported panoply of detrimental actions driven by the 
Aβ•CaSR signaling in NAHAs and human neurons [14,17–20,33,34,52]. Notably, the Aβ•CaSR 
signaling unique ability to simultaneously set off and release an amazing multiplicity of noxious 
effectors from human cortical neurons and astrocytes, testifies for its relevance to AD. Our findings 
further stress the view that pathological Aβ•CaSR signaling is a potential therapeutic target in AD 
[18,20,21,36–38]. On the other hand, they also show that extracellular Aβs surpluses induce NAHAs 
to over-release several proinflammatory agents through Aβ•CaSR-independent mechanisms. But 
these effects are placed downstream from Aβ•CaSR signaling, the upshots of which include the 
release of Aβs surpluses from human neurons and astrocytes [21]. As a final notation, we are aware 
that the other outstanding neuroinflammation player, i.e., human microglia, is missing from the 
experimental system presently used. However, we are confident that future work will overcome this 
limitation and throw further light onto the intricate mechanisms that hold sway in human AD-related 
neuroinflammation 
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